There is still a lot we do not know about why some prostate cancers grow slowly and are effectively benign and some are viciously malignant. This split leads so

There is still a lot we do not know about why some prostate cancers grow slowly and are effectively benign and some are viciously malignant. This split leads some health practitioners to either relax or ignore screening guidelines. Being able to better narrow things down so we can avoid overly aggressive treatment while at the same time being appropriately aggressive for those that have more malignant variants. (BTW, this is not just theoretical for me)